I'm posting a few historical medical journal articles I saved...

I'm posting a few historical medical journal articles I saved over the past few years as part of my investigation into the relevance of RHY's proteomic technology. I'm fundamentally interested in Proteomics v Genomics.

Rhythm's Colostat is 100% Proteomic (=cheap)
Competitor Cologuard is Genomic (=expensive)

(Noting Rhythm's science was originally developed by Trevor Lockett at the CSIRO over 12 years prior to this current commercialisation phase.)

As previously mentioned, I've been invested in this company since 2020 and follow its progress closely. I confidently doubled my holdings around the 7 cents mark.

2012 - The failure of protein cancer biomarkers to reachthe clinic: why, and what can be done to addressthe problem?
1741-7015-10-87.pdf
"In theory, biomarkers can serve many clinical needsfrom risk stratification to prognosis, screening, diagnosis, monitoring, patient subclassification, assessment ofdrug toxicity and prediction of therapeutic response. Tobring biomarkers to the clinic, it is mandatory to show auseful clinical application that is supported by the validation data. Only then will diagnostic companies investthe necessary (and very significant) funds to conductmulticenter clinical trials to show efficacy and receiveFDA approval."
"Eventually, the timewill likely come when biology and technology willadvance sufficiently to catalyze the needed and muchanticipated leap in cancer biomarkers."

2018 - Clinical Proteomics in Colorectal Cancer, a PromisingTool for Improving Personalised Medicine
proteomes-06-00049.pdf
"Predictive biomarkers of response to treatment are highly valuable and the search for thesebiomarkers is a major public health challenge. Indeed, the discovery of a biomarker, or a signature ofbiomarkers, capable of predicting the response of patients with colorectal cancer to a given radiotherapyand/or chemotherapy treatment would invariably have many advantages: First of all, for the patient,in avoiding physically and psychologically demanding treatment; secondly, for physicians, in guidingtheir clinical decisions; and finally, for reducing health care costs (Figure 2) [34]. Unfortunately, despitenumerous proteomic studies, no biomarkers identified after the discovery and/or validation stepsare currently the subject of clinical studies [102,103], and this problem is very well discussed byDiamandis et al. [102]. However, as shown in Tables 1 and 2, many proteins identified in the variousproteomic studies are found in Zhang’s proteogenomic study (*) [29]. Indeed, Zhang et al. showedthat the abundance of mRNA (DNA) transcripts did not efficiently predict the abundance of proteins. Thisobservation highlights the importance of proteogenomic integration to strengthen the data in thediscovery of biomarkers, or of potential therapeutic targets in colorectal cancer [29,103]."

Rhythm is uniquely placed. It holds patents in all major global jurisdictions for what appears to be the most advanced Proteomic Colorectal Cancer test to date. It's taken 15 years for them to reach this point.

Impressive new Rhythm CEO, David Atkins, has stated:
"One thing that puts us in a strong position is when you're screening tens of millions of individuals, economics becomes really important, and having a test that is relatively straightforward, using reagents and components that are relatively low cost, which is exactly what Rhythm in doing, is going to put us in a very competitive position."

This week we will see several new major investors coming in, injecting around $3-3.5 million. The funds will be used to progress the development of 2nd generation Colostat with US company Qansys, and for clinical validation.